<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Aktis Oncology, Inc. Common Stock — News on 6ix</title>
    <link>https://6ix.com/company/aktis-oncology-inc-common-stock</link>
    <description>Latest news and press releases for Aktis Oncology, Inc. Common Stock on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 21:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/aktis-oncology-inc-common-stock" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo697f1629cfec6970aced0b12.webp</url>
      <title>Aktis Oncology, Inc. Common Stock</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock</link>
    </image>
    <item>
      <title>Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-announces-presentation-of-first-clinical-imaging-and-dosimetry-data-for-aky-2519-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-announces-presentation-of-first-clinical-imaging-and-dosimetry-data-for-aky-2519-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting</guid>
      <pubDate>Tue, 21 Apr 2026 21:00:00 GMT</pubDate>
      <description>AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentationsData facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumors and normal tissues in patients with B7-H3 expressing solid tumorsPhase 1b clinical trial of AKY-2519 to start mid-2026 BOSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential o</description>
    </item>
    <item>
      <title>Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-appoints-industry-research-and-development-veteran-glenn-gormley-md-phd-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-appoints-industry-research-and-development-veteran-glenn-gormley-md-phd-to-its-board-of-directors</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 GMT</pubDate>
      <description>BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the Company’s newly established Science and Technology Committee of the Boa</description>
    </item>
    <item>
      <title>Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-announces-fda-clearance-of-investigational-new-drug-applications-for-aky-2519-and-provides-business-updates-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-announces-fda-clearance-of-investigational-new-drug-applications-for-aky-2519-and-provides-business-updates-and-full-year-2025-financial-results</guid>
      <pubDate>Mon, 30 Mar 2026 20:01:00 GMT</pubDate>
      <description>Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existin</description>
    </item>
    <item>
      <title>Aktis Oncology to Present at Upcoming March Investor Conferences</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-to-present-at-upcoming-march-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-to-present-at-upcoming-march-investor-conferences</guid>
      <pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
      <description>BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the following investor conferences in March 2026. TD Cowen 46th Annual Health Care Conference Da</description>
    </item>
    <item>
      <title>Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-receives-us-fda-fast-track-designation-for-aky-1189-a-nectin-4-miniprotein-radioconjugate</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-receives-us-fda-fast-track-designation-for-aky-1189-a-nectin-4-miniprotein-radioconjugate</guid>
      <pubDate>Tue, 24 Feb 2026 13:00:00 GMT</pubDate>
      <description>U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b trial of AKY-1189 enrolling patients with locally advanced or metastatic urothelial cancer and several other Nectin-4 expressing tumor types BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakt</description>
    </item>
    <item>
      <title>Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-announces-closing-upsized-113000966</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/aktis-oncology-announces-closing-upsized-113000966</guid>
      <pubDate>Tue, 13 Jan 2026 11:30:00 GMT</pubDate>
      <description>BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the closing of its upsized initial public offering of 17,650,000 shares of its common stock, at an initial public offering price of $18.00 per share, occurred on January 12, 2026. In addition, the und</description>
    </item>
    <item>
      <title>Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-pursue-strategic-sale-its-business-through-voluntary-chapter-11-process-0</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-pursue-strategic-sale-its-business-through-voluntary-chapter-11-process-0</guid>
      <pubDate>Mon, 16 Dec 2024 05:00:00 GMT</pubDate>
      <description>Committed to Full Continuity in Delivering Next-Generation BAW High-Band RF Filters to Customers Around the World Filing to Ensure Business Sold Free and</description>
    </item>
    <item>
      <title>Akoustis Receives an Additional Purchase Order for $13 Million XBAW® Filters from Existing Tier-1 Customer</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-receives-additional-purchase-order-13-million-xbawr-filters-existing-tier-1</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-receives-additional-purchase-order-13-million-xbawr-filters-existing-tier-1</guid>
      <pubDate>Tue, 13 Aug 2024 04:00:00 GMT</pubDate>
      <description>Charlotte, NC, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Receives an Additional Purchase Order for $13 Million XBAW® Filters from Existing Tier-1 Customer</description>
    </item>
    <item>
      <title>Akoustis Announces Leadership Transition</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-announces-leadership-transition-2024-08-08</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-announces-leadership-transition-2024-08-08</guid>
      <pubDate>Thu, 08 Aug 2024 04:00:00 GMT</pubDate>
      <description>Charlotte, NC, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Akoustis Announces Leadership Transition Charlotte, NC, August 8, 2024 (GLOBE NEWSWIRE) - Akoustis</description>
    </item>
    <item>
      <title>Akoustis Secures $8 Million in Volume XBAW® Orders with Tier-1 Customer</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-secures-8-million-volume-xbawr-orders-tier-1-customer-2024-07-09</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-secures-8-million-volume-xbawr-orders-tier-1-customer-2024-07-09</guid>
      <pubDate>Tue, 09 Jul 2024 04:00:00 GMT</pubDate>
      <description>Tier-1 Customer to Utilize Multiple XBAW® Filters for Wi-Fi 6E and 7 Access PointsVolume Orders to Satisfy Customer’s Demand Through Fiscal Year 2025</description>
    </item>
    <item>
      <title>Akoustis Receives $2 Million in Volume Orders for Wi-Fi 7 Program from Tier-1 Carrier</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-receives-2-million-volume-orders-wi-fi-7-program-tier-1-carrier-2024-06-27</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-receives-2-million-volume-orders-wi-fi-7-program-tier-1-carrier-2024-06-27</guid>
      <pubDate>Thu, 27 Jun 2024 04:00:00 GMT</pubDate>
      <description>Tier-1 Customer to Use Akoustis’ Next-Generation 5.5 and 6.5 GHz Wi-Fi XBAW® Filters in Tri-Band 4x4 MIMO RouterSecured Wi-Fi 7 Filter Orders to Support</description>
    </item>
    <item>
      <title>Akoustis Announces $10 Million Registered Direct Offering  Priced At-The-Market Under Nasdaq Rules</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-announces-dollar10-million-registered-direct-offering-priced-at-the-market-under</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-announces-dollar10-million-registered-direct-offering-priced-at-the-market-under</guid>
      <pubDate>Wed, 22 May 2024 04:00:00 GMT</pubDate>
      <description>Charlotte, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (Nasdaq: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer</description>
    </item>
    <item>
      <title>Akoustis Completes Rollout of its XBAW® Design Updates</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-completes-rollout-of-its-xbawr-design-updates-2024-05-22</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-completes-rollout-of-its-xbawr-design-updates-2024-05-22</guid>
      <pubDate>Wed, 22 May 2024 04:00:00 GMT</pubDate>
      <description>Charlotte, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer</description>
    </item>
    <item>
      <title>Akoustis Reports Third Quarter FY24 Results</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-reports-third-quarter-fy24-results-2024-05-13</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-reports-third-quarter-fy24-results-2024-05-13</guid>
      <pubDate>Mon, 13 May 2024 04:00:00 GMT</pubDate>
      <description>Q3 Revenue Up 7% Quarter-Over-Quarter Filter-Related Revenue Up 13% Quarter-Over-Quarter, Third Highest in Company History Growth, Cost Savings Initiatives,</description>
    </item>
    <item>
      <title>Akoustis to Webcast Q3FY24 Results on May 13 at 8:00 am ET</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-to-webcast-q3fy24-results-on-may-13-at-800-am-et-2024-05-07</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-to-webcast-q3fy24-results-on-may-13-at-800-am-et-2024-05-07</guid>
      <pubDate>Tue, 07 May 2024 04:00:00 GMT</pubDate>
      <description>Charlotte, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer</description>
    </item>
    <item>
      <title>Akoustis Receives Two Design Wins with Tier-1 Network Infrastructure Customer</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-receives-two-design-wins-with-tier-1-network-infrastructure-customer-2024-05</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-receives-two-design-wins-with-tier-1-network-infrastructure-customer-2024-05</guid>
      <pubDate>Wed, 01 May 2024 04:00:00 GMT</pubDate>
      <description>Tier-1 Customer to Use High-Performance Akoustis XBAW® Filters for Two Wi-Fi 7 Fixed Wireless Access Enterprise and Home Gateway PlatformsCompany Has</description>
    </item>
    <item>
      <title>Akoustis Secures Design Win and Volume Orders for Wi-Fi 7 Solution with Tier-1 Enterprise Class OEM</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-secures-design-win-and-volume-orders-for-wi-fi-7-solution-with-tier-1</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-secures-design-win-and-volume-orders-for-wi-fi-7-solution-with-tier-1</guid>
      <pubDate>Mon, 08 Apr 2024 04:00:00 GMT</pubDate>
      <description>Tier-1 Customer to Use High-Performance Akoustis XBAW® Filters in 4X4 MU-MIMO Enterprise Router PlatformCompany Has Received Volume Orders to Facilitate</description>
    </item>
    <item>
      <title>Akoustis Introduces Two New 2.4 GHz BAW RF Filters for Wi-Fi Automotive and Access Point Applications</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-introduces-two-new-24-ghz-baw-rf-filters-for-wi-fi-automotive-and-access</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-introduces-two-new-24-ghz-baw-rf-filters-for-wi-fi-automotive-and-access</guid>
      <pubDate>Wed, 03 Apr 2024 04:00:00 GMT</pubDate>
      <description>New High-Performance 2.4 GHz Channel 1-11 XBAW® Bandedge RF Filters for Improved Wi-Fi Range and Coexistence with LTEThe A10124 and A10324 is Currently</description>
    </item>
    <item>
      <title>Akoustis to Attend the 36th Annual Roth Conference on March 17-19, 2024</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-to-attend-the-36th-annual-roth-conference-on-march-17-19-2024-2024-03-11</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-to-attend-the-36th-annual-roth-conference-on-march-17-19-2024-2024-03-11</guid>
      <pubDate>Mon, 11 Mar 2024 04:00:00 GMT</pubDate>
      <description>Charlotte, N.C., March 11, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device</description>
    </item>
    <item>
      <title>Akoustis to Attend GOMACTech 2024 in Charleston from March 19-20</title>
      <link>https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-to-attend-gomactech-2024-in-charleston-from-march-19-20-2024-02-15</link>
      <guid isPermaLink="true">https://6ix.com/company/aktis-oncology-inc-common-stock/news/akoustis-to-attend-gomactech-2024-in-charleston-from-march-19-20-2024-02-15</guid>
      <pubDate>Thu, 15 Feb 2024 05:00:00 GMT</pubDate>
      <description>Charlotte, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer</description>
    </item>
  </channel>
</rss>